These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 19240170)

  • 1. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma.
    Michaud WA; Nichols AC; Mroz EA; Faquin WC; Clark JR; Begum S; Westra WH; Wada H; Busse PM; Ellisen LW; Rocco JW
    Clin Cancer Res; 2009 Mar; 15(5):1645-54. PubMed ID: 19240170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer.
    Nichols AC; Finkelstein DM; Faquin WC; Westra WH; Mroz EA; Kneuertz P; Begum S; Michaud WA; Busse PM; Clark JR; Rocco JW
    Clin Cancer Res; 2010 Apr; 16(7):2138-46. PubMed ID: 20233885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer.
    Bauer JA; Kumar B; Cordell KG; Prince ME; Tran HH; Wolf GT; Chepeha DB; Teknos TN; Wang S; Eisbruch A; Tsien CI; Urba SG; Worden FP; Lee J; Griffith KA; Taylor JM; D'Silva N; Wang SJ; Wolter KG; Henson B; Fisher SG; Carey TE; Bradford CR
    Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S106-8. PubMed ID: 17848273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells.
    Li C; Li R; Grandis JR; Johnson DE
    Mol Cancer Ther; 2008 Jun; 7(6):1647-55. PubMed ID: 18566236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy.
    Gasparini G; Bevilacqua P; Bonoldi E; Testolin A; Galassi A; Verderio P; Boracchi P; Guglielmi RB; Pezzella F
    Clin Cancer Res; 1995 Nov; 1(11):1375-83. PubMed ID: 9815934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy.
    Sharma H; Sen S; Lo Muzio L; Mariggiò A; Singh N
    Cancer Biol Ther; 2005 Jul; 4(7):720-7. PubMed ID: 15917659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association of Bcl-xL and p53 expression with survival outcomes in oropharyngeal cancer.
    Ziai H; Alenazi A; Hearn M; O'Connell DA; Puttagunta L; Barber B; Harris JR; Seikaly H; Biron VL
    Cancer Biomark; 2019; 24(2):141-151. PubMed ID: 30614804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TTP mediates cisplatin-induced apoptosis of head and neck cancer cells by down-regulating the expression of Bcl-2.
    Park SB; Lee JH; Jeong WW; Kim YH; Cha HJ; Joe Y; Chung HT; Cho WJ; Do JW; Lee BJ; Park JW; Ko BK
    J Chemother; 2015 Jun; 27(3):174-80. PubMed ID: 25604244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-xL expression and regulation in the progression, recurrence, and cisplatin resistance of oral cancer.
    Alam M; Mishra R
    Life Sci; 2021 Sep; 280():119705. PubMed ID: 34111459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
    Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL.
    Bauer JA; Trask DK; Kumar B; Los G; Castro J; Lee JS; Chen J; Wang S; Bradford CR; Carey TE
    Mol Cancer Ther; 2005 Jul; 4(7):1096-104. PubMed ID: 16020667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation.
    van den Broek GB; Wildeman M; Rasch CR; Armstrong N; Schuuring E; Begg AC; Looijenga LH; Scheper R; van der Wal JE; Menkema L; van Diest PJ; Balm AJ; van Velthuysen ML; van den Brekel MW
    Int J Cancer; 2009 Jun; 124(11):2643-50. PubMed ID: 19253368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells.
    Oliver CL; Bauer JA; Wolter KG; Ubell ML; Narayan A; O'Connell KM; Fisher SG; Wang S; Wu X; Ji M; Carey TE; Bradford CR
    Clin Cancer Res; 2004 Nov; 10(22):7757-63. PubMed ID: 15570010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
    Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
    Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
    Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
    J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
    Li R; Zang Y; Li C; Patel NS; Grandis JR; Johnson DE
    Mol Pharmacol; 2009 May; 75(5):1231-9. PubMed ID: 19246337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival.
    Sandulache VC; Ow TJ; Daram SP; Hamilton J; Skinner H; Bell D; Rosenthal DI; Beadle BM; Ang KK; Kies MS; Johnson FM; El-Naggar AK; Myers JN
    Head Neck; 2013 Oct; 35(10):1454-60. PubMed ID: 23018868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas.
    Sedaghat AR; Zhang Z; Begum S; Palermo R; Best S; Ulmer KM; Levine M; Zinreich E; Messing BP; Gold D; Wu AA; Niparko KJ; Kowalski J; Hirata RM; Saunders JR; Westra WH; Pai SI
    Laryngoscope; 2009 Aug; 119(8):1542-9. PubMed ID: 19522004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation.
    Patel K; Wen J; Magliocca K; Muller S; Liu Y; Chen ZG; Saba N; Diaz R
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1015-22. PubMed ID: 25205430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AKR1C3 is a biomarker and druggable target for oropharyngeal tumors.
    Peraldo-Neia C; Ostano P; Mello-Grand M; Guana F; Gregnanin I; Boschi D; Oliaro-Bosso S; Pippione AC; Carenzo A; De Cecco L; Cavalieri S; Micali A; Perrone F; Averono G; Bagnasacco P; Dosdegani R; Masini L; Krengli M; Aluffi-Valletti P; Valente G; Chiorino G
    Cell Oncol (Dordr); 2021 Apr; 44(2):357-372. PubMed ID: 33211282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.